Expertise in
19
conditions

Nicolas Schleinitz

CHU Caen
Caen, FR 
Expertise in
19
conditions
CHU Caen
Caen, FR 

Overview

Nicolas Schleinitz practices practicing medicine in Caen, France.

Mr. Schleinitz is highly rated in 19 conditions, according to our data. His clinical expertise encompasses IgG4-Related Disease, Hypereosinophilic Syndrome, Granulomatosis with Polyangiitis, Vasculitis, and Kidney Transplant.

He is actively involved in clinical research, co-authoring 176 peer reviewed articles and participating in 6 clinical trials.

Gender

Male

Locations

CHU Caen
Caen, France
Other Locations
CHU Marseille
Marseille, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Outcome of Acquired Haemophilia With Steroid Combined With Cyclophosphamide Versus Steroid Combined With Rituximab (CREHA Study)
Outcome of Acquired Haemophilia With Steroid Combined With Cyclophosphamide Versus Steroid Combined With Rituximab (CREHA Study)
Enrollment Status: Completed
Publish Date: March 24, 2026
Intervention Type: Drug
Study Drugs: Steroid, Cyclophosphamide, Rituximab
Study Phase: Phase 3
Efficacy of Remission-induction Regimen With Infliximab for Severe Extrathoracic Sarcoidosis (EFIRTES STUDY)
Efficacy of Remission-induction Regimen With Infliximab for Severe Extrathoracic Sarcoidosis (EFIRTES STUDY)
Enrollment Status: Completed
Publish Date: February 07, 2024
Intervention Type: Drug
Study Drug: Infliximab
Study Phase: Phase 3
C5a Receptor Expression in Circulating Myeloid Cells in ARDS Secondary to COVID-19
C5a Receptor Expression in Circulating Myeloid Cells in ARDS Secondary to COVID-19
Enrollment Status: Completed
Publish Date: August 14, 2023
Intervention Type: Other
Study Phase: Not Applicable
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Enrollment Status: Terminated
Publish Date: May 16, 2023
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
Enrollment Status: Completed
Publish Date: November 23, 2022
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Phase IIa, Single Blind, Randomized, Study to Evaluate the Safety, the Immunogenicity, and the Clinical and Biological Efficacy of IFNα-Kinoid (IFN-K) in Adult Subjects With Dermatomyositis
A Phase IIa, Single Blind, Randomized, Study to Evaluate the Safety, the Immunogenicity, and the Clinical and Biological Efficacy of IFNα-Kinoid (IFN-K) in Adult Subjects With Dermatomyositis
Enrollment Status: Withdrawn
Publish Date: January 03, 2020
Intervention Type: Other, Biological
Study Phase: Phase 2
View 5 Less Clinical Trials

176 Total Publications

Occupational category, job type, and sarcoidosis: Findings from a French multicenter study.
Occupational category, job type, and sarcoidosis: Findings from a French multicenter study.
Journal: Pulmonology
Published: June 24, 2026

Frequently Asked Questions about Nicolas Schleinitz

Is Nicolas Schleinitz a top-rated expert for IgG4-Related Disease?

MediFind is an objective health platform that identifies experts based on real-world data. Nicolas Schleinitz is classified as an Elite expert for IgG4-Related Disease, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Nicolas Schleinitz participate in research or clinical trials?

Yes. Nicolas Schleinitz has published 176 articles and abstracts on conditions like IgG4-Related Disease. You can view a list of Nicolas Schleinitz's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Schleinitz's expertise for a condition
ConditionClose
View All 17 Advanced Conditions
View All 85 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile